Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Community Allies
  • Our Work
    • Advancing Research
    • Changing Policy
    • Evolving Education
    • The Virtual Trip
  • News
    • Updates
    • Newsletter
    • Press Releases
    • MAPS Bulletin
    • MAPS in the Media
    • Newsroom
  • Take Action
    • MAPS Membership
    • Donate
    • Volunteer
    • Careers
    • Community Events
    • Resources
    • Integration Station
    • Music Is the Bridge
  • Store
    • The Dose (New Items)
    • Learning
    • Apparel
    • Accessories
    • Bookshop
Login
  • Donate
0

Medical Marijuana Research News

October 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On October 15, 2022, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous progress reports were released for quarters ending in January, April, and July. …
October 15, 2022

Response from FDA Regarding Request to Lift Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On August 30, 2022, the FDA responded to MAPS’ request to lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2), citing an incomplete response to the hold. …
August 30, 2022

Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Continued Partial Clinical Hold Response

On August 16, 2022, MAPS submitted a complete response to the FDA addressing the continued partial clinical hold letter, received on December 27, 2021.
August 16, 2022

Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)

On July 21, 2022, a general medical and psychiatric practice in Steinheim, Germany, released a statement about their use of cannabis to treat patients with symptoms of posttraumatic stress disorder (PTSD). …
July 31, 2022

July 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On July 15, 2022, MAPS released a grant progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous grant reports were released in January and April. Read the July 2022 grant …
July 15, 2022

Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Regulatory Correspondences with FDA

Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
June 13, 2022

April 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On April 15, 2022, MAPS wrote the second progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The first report was for the reporting period ending January 15, 2022. Read the …
April 15, 2022

January 2022 Quarterly Performance Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On January 14, 2022, MAPS released the first MRA VMR Grant Update for the reporting period ending January 15, 2022 for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The quarterly performance …
January 15, 2022

MAPS Awarded $12.9 Million Grant from Michigan to Expand Cannabis Research for Veterans with PTSD

MAPS) has been awarded a $12,979,050 grant from Michigan’s $20 million competitive 2021 Veteran Marijuana Research Grant Program. The program, which is funded by adult-use marijuana retail taxes, is …
August 10, 2021

FDA Places a Partial Clinical Hold on MAPS Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

May 10, 2021

U.S. Attorney General William Barr Receives Formal Letter from Six U.S. Senators Regarding the Advancement of Research-Grade Marijuana Production

On April 2, 2019, six United States Senators sent Attorney General William Barr a formal letter to follow-up about pending applications to manufacture marijuana for scientific research. “Our nation’s …
April 2, 2019

U.S. Senators Schatz and Booker Formally Advocate for Expediting Approval of New Research-Grade Marijuana Manufacturers

On March 28, 2019, United States Senators Brian Schatz and Cory A. Booker of the Senate Judiciary Committee sent a formal letter to Attorney General William Barr regarding the delay of licensing new manufacturers …
March 28, 2019

Posts pagination

Newer Posts Page 1 … Page 3 … Page 23 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
    • Global Affiliates
  • Our Work
    • Psychedelic Fundamentals
    • The Virtual Trip
    • U.S. MDMA Therapy Education
    • Health Equity
    • Policy & Advocacy
  • Advancing Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • MAPS Membership
    • Donate
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up

  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2026 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mail checks to: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.
Designed with WordPress. Hosted by Pressable.

Download our Integration Guide

Just enter your email in order to download our Integration Guide